NFATC2 and melanoma: NFATc2 silencing by shRNA or treatment of melanoma cells with inhibitors of NFATc2 (AM404), c-Myc (10058-F4), FOXM1 (Siomycin A) or EZH2 (GSK126) reduced significantly migratory activity (Fig. 5a, b), by wound healing assay, and invasive ability (Fig. 5c).